The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma.
 
Jennifer Ann Wargo
Honoraria - GlaxoSmithKline; Roche Pharma AG
Consulting or Advisory Role - GlaxoSmithKline; Roche Pharma AG
Speakers' Bureau - Dava Oncology
Research Funding - Genentech (Inst); GlaxoSmithKline (Inst); Prometheus (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche Pharma AG
 
Donald P. Lawrence
No Relationships to Disclose
 
Zachary A Cooper
No Relationships to Disclose
 
Dennie T. Frederick
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Adriano Piris
No Relationships to Disclose
 
Krista M. Rubin
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck
 
Riley Fadden
No Relationships to Disclose
 
Alexandre Reuben
No Relationships to Disclose
 
Lee Starker
No Relationships to Disclose
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Lilly; Merck; Momenta Pharmaceuticals; Novartis; Oncoceutics; Sanofi; Viralytics; ZIOPHARM Oncology
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - GlaxoSmithKline; Sanofi
 
Arlene Sharpe
No Relationships to Disclose
 
Ryan J. Sullivan
Consulting or Advisory Role - Astex Pharmaceuticals